ProQR Therapeutics N.V. (PRQR)
Automate Your Wheel Strategy on PRQR
With Tiblio's Option Bot, you can configure your own wheel strategy including PRQR - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol PRQR
- Rev/Share 0.1805
- Book/Share 0.7496
- PB 2.2406
- Debt/Equity 0.2135
- CurrentRatio 4.0953
- ROIC -0.2673
- MktCap 176724066.627
- FreeCF/Share -0.3606
- PFCF -4.6544
- PE -5.8596
- Debt/Assets 0.1111
- DivYield 0
- ROE -0.5358
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 3
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | PRQR | Cantor Fitzgerald | -- | Overweight | -- | $8 | April 29, 2025 |
| Initiation | PRQR | Evercore ISI | -- | Outperform | -- | $5 | April 29, 2025 |
| Upgrade | PRQR | Citigroup | Neutral | Buy | -- | $4 | March 10, 2025 |
| Initiation | PRQR | Oppenheimer | -- | Outperform | -- | $15 | Jan. 10, 2025 |
News
ProQR Announces Upcoming Scientific Presentations at ASGCT and TIDES Conferences
Published: May 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
LEIDEN, Netherlands & CAMBRIDGE, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced that it will present at two upcoming scientific conferences: the American Society of Gene & Cell Therapy (ASGCT) 28th Annual Meeting, taking place May 13-17, 2025, in New Orleans, Louisiana and the TIDES USA 2025: Oligonucleotide and Peptide Therapeutics Conference, being held May 19-22, 2025, in San Diego, California.
Read More
ProQR Announces First Quarter 2025 Operating and Financial Results
Published: May 08, 2025 by: GlobeNewsWire
Sentiment: Neutral
LEIDEN, Netherlands & CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer RNA editing technology platform, today reported its financial and operating results for the first quarter ended March 31, 2025, and provided a business update.
Read More
ProQR Announces Annual General Meeting of Shareholders to be Held June 3, 2025
Published: May 01, 2025 by: GlobeNewsWire
Sentiment: Neutral
LEIDEN, Netherlands & CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.
Read More
ProQR (PRQR) Reports Q4 Loss, Lags Revenue Estimates
Published: March 13, 2025 by: Zacks Investment Research
Sentiment: Negative
ProQR (PRQR) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to loss of $0.08 per share a year ago.
Read More
About ProQR Therapeutics N.V. (PRQR)
- IPO Date 2014-09-18
- Website https://www.proqr.com
- Industry Biotechnology
- CEO Mr. Daniel Anton de Boer
- Employees 166